Relay Therapeutics (RLAY) Cash from Financing Activities (2019 - 2026)
Relay Therapeutics (RLAY) reported Cash from Financing Activities of $138.8 million for Q1 2026, up 14758.89% on a QoQ basis from $934000.0 in Q4 2025.
Relay Therapeutics (RLAY) has 8 years of Cash from Financing Activities data on file, last reported at $138.8 million in Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $138.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.5 million (changed N/A YoY) and the FY2025 annual result came in at $1.6 million, down 99.41% from the prior year.
- Cash from Financing Activities climbed to $138.8 million in Q1 2026 per RLAY's latest filing, from $934000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $285.9 million in Q3 2022 and bottomed at $17000.0 in Q3 2025.
- The 5-year median for Cash from Financing Activities is $2.0 million (2022), against an average of $49.0 million.
- The widest annual swing landed in 2022, when Cash from Financing Activities surged 31592.35%; it then tumbled 99.99% in 2025.
- Tracing RLAY's Cash from Financing Activities over 5 years: stood at $1.2 million in 2022, then jumped by 1779.76% to $21.9 million in 2023, then plunged by 96.35% to $800000.0 in 2024, then grew by 16.75% to $934000.0 in 2025, then soared by 14758.89% to $138.8 million in 2026.
- Per Business Quant, the three latest RLAY Cash from Financing Activities figures stand at $138.8 million (Q1 2026), $934000.0 (Q4 2025), and $17000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | 138.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 138.78 Mn |
| Mar 31, 2026 | 138.78 Mn |
| Dec 31, 2025 | 934,000.00 |
| Dec 31, 2025 | 934,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Sep 30, 2024 | 218.89 Mn |
| Sep 30, 2024 | 218.89 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 48.92 Mn |
| Mar 31, 2024 | 48.92 Mn |
| Dec 31, 2023 | 21.92 Mn |
| Dec 31, 2023 | 21.92 Mn |
| Sep 30, 2023 | 9.46 Mn |
| Sep 30, 2023 | 9.46 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Dec 31, 2022 | 1.17 Mn |
| Dec 31, 2022 | 1.17 Mn |
| Sep 30, 2022 | 285.87 Mn |
| Sep 30, 2022 | 285.87 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 883,000.00 |
| Mar 31, 2022 | 883,000.00 |
| Dec 31, 2021 | 384.01 Mn |
| Dec 31, 2021 | 384.01 Mn |
| Sep 30, 2021 | 902,000.00 |
| Sep 30, 2021 | 902,000.00 |
| Jun 30, 2021 | 1.12 Mn |
| Jun 30, 2021 | 1.12 Mn |
| Mar 31, 2021 | 2.06 Mn |
| Mar 31, 2021 | 2.06 Mn |
| Dec 31, 2020 | 56,000.00 |
| Dec 31, 2020 | 56,000.00 |
| Sep 30, 2020 | 426.20 Mn |
| Sep 30, 2020 | 426.20 Mn |
| Jun 30, 2020 | -93,000.00 |
| Jun 30, 2020 | -93,000.00 |
| Mar 31, 2020 | 351,000.00 |
| Mar 31, 2020 | 351,000.00 |
| Dec 31, 2019 | -227,000.00 |
| Dec 31, 2019 | -227,000.00 |
| Sep 30, 2019 | 116,000.00 |
| Sep 30, 2019 | 116,000.00 |